Table 1.
Baseline Characteristics Table. This table includes the baseline characteristics of the included randomized controlled trials which includes trial design, follow up time, number of participants, mean age, dose of vitamin D, frequency of vitamin D, primary outcome and if reported baseline plasma vitamin D concentration of participants.
| Name, Year | Design | Follow- Up (years) | Number of Participants (mean age in years) | Dose and Compound | Primary Outcome | Baseline 25-hydroxyvitamin D Concentration |
|---|---|---|---|---|---|---|
| Baron 2016 | Double-blind, placebo controlled | 3 or 5 years | 2259 patients with prior colonic adenoma (58 years) | 1000 IU of vitamin D daily | Adenoma occurrence | 24.4 ng/mL |
| Brazier 2005 | Double-blind, placebo controlled | 1 year | 192 women (74.6 years) | 500 mg calcium carbonate and vitamin D 400 IU taken twice daily | Renal function | 7.2 ng/mL |
| Ford 2014 | Double-blind, placebo controlled | 2 years | 5292 participants with prior low trauma fracture (77.5 years) | 800 IU of vitamin D daily | Fracture | n/a |
| Gallagher 2012 | Double-blind placebo controlled | 1 year | 163 postmenopausal women (67 years) | 400, 800, 1600, 240, 3200, 4000, 4800 IU/ daily or placebo | 25(OH)D and PTH levels | 7.6 ng/mL |
| Gulseth 2017 | Double-blind, placebo controlled | 0.5 year | 62 men and women with type 2 diabetes and vitamin D deficiency (55.6 years) | 400,000 IU oral vitamin D3 or placebo. Those randomized to the vitamin D group received an additional 200,000 IU if 25(OH)D level was less than 100 nmol/L after 4 weeks. | Insulin sensitivity | 15.2 ng/ml |
| Inkovaara 1983 | Double-blind, placebo controlled | 9 months | 87 patients (79.5 years) | 1000 IU/day of vitamin D or placebo | Bone fracture | n/a |
| Jackson 2006 | Double-blind, placebo controlled | 7 years | 36,282 postmenopausal women (62.4 years) | 400 IU of vitamin D daily or placebo | Hip Fracture | n/a |
| Jin 2016 | Double-blind, placebo controlled | 2 years | 413 patients with symptomatic knee osteoarthritis (63.2 years) | 50,000 IU of vitamin D per month vs. placebo | Change in tibial cartilage volume, change in the Western Ontario and McMaster Universities Arthritis Index pain score | 17.48 ng/ml |
| Jorde 2016 | Double-blind, placebo controlled | 5 years | 511, patients with prediabetes (62 years) | 20,000 IU/week or placebo | Progression to type 2 diabetes | 24.0 ng/ml |
| Komulainen 1999 | Double-blind, placebo controlled | 5 years | 343 women (52.6 years) | 300 IU daily and 100 IU daily or placebo | Bone Mineral Density | n/a |
| Matrineau 2015 (ViDiAs) | Double-blind, placebo controlled | 1 year | 250 adults with asthma (48 years) | 3 mg of vitamin D3 or placebo | Time to first asthma exacerbation and time to first upper respiratory tract infection | 19.8 ng/mL |
| Matrineau 2015 (ViDiFlu) | Double blind, placebo controlled | 1 year | 240 patients (67.1 years) | 2.4 mg of vitamin D every 2 months + 10 µg daily or 3 mg every 2 months vs. placebo | Time to first acute respiratory infection | 17.2 ng/mL |
| Miskulin 2016 | Double-blind, placebo controlled | 0.5 year | 276 vitamin D deficient patients with end-stage renal disease (61.1 years) | 50,000 IU weekly for 6 months | Change in epotien dose | 16.4 ng/mL |
| Prince 2008 | Double-blind, placebo controlled | 1 year | 302 vitamin D deficient women with a history of fall in the previous year (77.2 years) | 1000 IU per day of ergocalciferol | Falls | 17.9 ng/mL |
| Sanders 2010 | Double-blind, placebo controlled | 3–5 years | 2256 women (76 years) | 500,000 IU yearly of vitamin D | Falls and fractures | 19.6 ng/mL |
| Scragg 2017 | Double-blind, placebo controlled | 3.3 years | 5108 patients (65.9 years) | 200,000 IU initial dose followed by 100,000 IU q4 weeks | CVD and death | 25.4 ng/mL |
| Trivedi 2003 | Double-blind, placebo controlled | 5 years | 2686 participants (74.8 years) | 100,000 IU of vitamin D every 4 months over 5 years | Fracture incidence and total mortality | n/a |
| VITAL Trial | Double-blind, placebo controlled | 5.3 years | 25,871 patients (67.1 years) | 2000 IU/day of vitamin D3 versus placebo | Major cardiovascular events and invasive cancer of any kind | 30.8 mg/mL (measured in 61% of baseline population) |
| Witham 2013 | Double-blind, placebo controlled | 1 year | 159 participants with hypertension (77 years) | 100,000 IU of vitamin D every 3 months for 1 year | Change in office blood pressure | 18 ng/mL |
| Witham 2010 | Double-blind, placebo controlled | 0.38 year | 105 patients with systolic heart failure (79.8 years) | 100,000 IU at baseline at and at 10 weeks vs. placebo | 6 min walk test | 8.8 ng/mL |
| Zitterman 2017 | Double blind, placebo controlled | 3 year | 400 patients with heart failure (55 years) | 4000 IU/day of vitamin D versus placebo | All-cause mortality | 13.2 ng/mL |